P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

February 2010

Features

Interventions to Curb the Overuse of Acid-Suppressive Medications on an Inpatient General Medicine Service

A retrospective review was conducted to assess the effect of various interventions on inappropriate prescribing of acid-suppressive agents in the hospital. ­Providing educational lectures was helpful, but adding a pharmacist to the health care team resulted in the greatest decline in inappropriate use of these drugs.
Randolph E. Regal, BS, PharmD; Amanda D. Osta, MD; and Vikas I. Parekh, MD

Pharmacological and Clinical Differences Between Low-Molecular-Weight Heparins

Implications for Prescribing Practice and Therapeutic Interchange

Although low-molecular-weight heparins (LMWHs) have similar antithrombotic effects, they differ in their pharmacological and biochemical profiles. The authors discuss therapeutic interchange programs for currently available LMWHs and the risks to patients when agents are not clinically interchangeable.
Geno J. Merli, MD, and James B. Groce, PharmD

Meeting Highlights

American Society of Hematology, 51st Annual Meeting and Exposition

Drugs discussed include dasatinib (Sprycel), nilotinib (Tasigna), and imatinib (Gleevec) for patients with chronic myelogenous leukemia; deferasirox (Exjade) for beta-thalassemia major with iron overload; eculizumab (Soliris) for thrombocytopenia; and romiplostim (Nplate) for myelodysplastic syndromes.
Walter Alexander

Pharmaceutical Approval Update

Topics include an influenza vaccine (Fluzone High-Dose) to prevent virus subtypes A and B in older patients; von Willebrand factor/coagulation factor VIII complex (Wilate) to treat spontaneous and trauma-induced bleeding in patients with von Willebrand’s disease; and tranexamic acid (Lysteda) for heavy menstrual bleeding.
Marvin M. Goldenberg, PhD, RPh, MS

Departments

Editorial

Taking AAIM

David B. Nash, MD, MBA, ­discusses the impact of health care reform on academic departments of medicine and their affiliated training programs.
David B. Nash, MD, MBA

Medication Errors

Tablet Splitting—Only If You “Half” To

Matthew Grissinger, RPh, FASCP, explains how to ensure safety and minimize risks when oral tablets need to be split.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

FDA Plans to Simplify Formats for Consumer Pharmacy Materials

Stephen Barlas discusses the FDA’s plans to simplify the labeling of consumer medical information.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Actemra to Wilate, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.

Drug Forecast

Febuxostat (Uloric), A New Treatment Option for Gout

Dr. Avena-Woods and Dr. Hilas review febuxostat (Uloric) for the treatment of gout.
Carmela Avena-Woods, PharmD, and Olga Hilas, PharmD, MPH, BCPS, CGP